home
•
contacts
•
sitemap
•
japan
•
search
About
Company Overview
History
Management Team
Board of Directors
Locations
Careers
Pipeline
BTG Pipeline
Partnered Programmes
Marketed Products
Business Development
Our Focus
Partnering Opportunities
Contacts
Investors
Share Price Data
Stock Exchange Announcements
Press Releases
Financial Reports & Accounts
Financial Results
Presentations
BTG Share Dealing Facility
Email Alerts
Financial Calendar
Corporate Governance
Corporate Social Responsibility
Investor Contacts
News
Press Releases
Stock Exchange Announcements
Events
Publications
Email Alerts
Media Contact
Home
About
Company Overview
History
Management Team
Board of Directors
Locations
European Office Directions
US Office Directions
Careers
Pipeline
BTG Pipeline
Varisolve
®
BGC20-0582
BGC20-0166
BGC20-1259
BGC20-1531
BGC20-0134
Partnered Programmes
Campath
®
CB7630 (abiraterone)
TRX4
Misopess™
ABIO-0801
Juvidex™
Modafinil Combination
ONX 0801
β-Amyloid Inhibitors
Marketed Products
Business Development
Our Focus
Partnering Opportunities
Contacts
Investors
Share Price Data
Stock Exchange Announcements
Press Releases
Financial Reports & Accounts
Archive
Financial Results
Archive
Presentations
BTG Share Dealing Facility
Email Alerts
Financial Calendar
Corporate Governance
Corporate Social Responsibility
Investor Contacts
News
Press Releases
Stock Exchange Announcements
Events
Publications
Archive
Email Alerts
Media Contact
Contacts
BTG Japan
会社概要
自社開発品目
重点疾患領域
事業提携について
連絡先
Legal Notice
Accessibility
Recommended all share offer
AQ4N
Product
AQ4N
Licensee
Novacea, Inc
Indication
Solid tumours
Phase
Phase I/II
Description
Pro-drug of AQ4, a potent topoisomerase II inhibitor that is activated under hypoxic conditions.
Return to Pipeline
© BTG International Ltd 2008 •
Legal Notice
•
Accessibility
Product